

**Supplementary Table 1.** Characteristics of Selected Studies from India Evaluating NUDT and TPMT Polymorphisms

Author	Place	No. of participants	Clinical characteristic	NUDT	TPMT	TPMT-2	TPMT-3A	TPMT-3B	TPMT-3C
Banerjee et al. <sup>1</sup>	Hyderabad	935	IBD	134 (14.33) Heterozygous: 121 Homozygous: 13	-	-	-	-	-
Davavala et al. <sup>2</sup>	Mumbai	126	IBD: 105 AIH: 16 Others: 5	-	6 (4.77) All heterozygous	-	-	-	-
Desire et al. <sup>3</sup>	Vellore	98	ALL (pediatric and adult)	-	5 (5.10)	-	-	-	5 (5.10) <sup>b</sup>
Shah et al. <sup>4</sup>	Mumbai	370	IBD	40/206 (19.42)	13/370 (3.51)	-	-	-	22/206 (10.7)
Umamaheswaran et al. <sup>5</sup>	Pondicherry	608	Healthy population	-	15 (2.46)	-	-	-	15 (2.46)
Sadik et al. <sup>6</sup>	Hyderabad	150	Healthy population	-	-	-	-	-	-
Naushad et al. <sup>7</sup>	Hyderabad	2,000	Healthy population	262 (13.10)	104 (5.20)	-	7 (0.35) (*3A*3B and*3C together)	29 (1.45)	70 (3.50)
Murugesan et al. <sup>8</sup>	Manipal	326	Healthy population	-	9 (2.76)	2 (0.61)	-	2 (0.61)	5 (1.53)
Linga et al. <sup>9</sup>	Hyderabad	72	Pediatric ALL	-	3 (4.17)	1 (1.38)	1 (1.38)	-	1 (1.38)
Khera et al. <sup>10</sup>	Chandigarh	63	Pediatric ALL	6 (9.52)	2 (3.17)	-	-	-	-
Kapoor et al. <sup>11</sup>	Delhi	71	Pediatric ALL	-	7 (9.85)	3 (4.23)	1 (1.41)	-	3 (4.23)
Kapoor et al. <sup>12</sup>	Delhi	120+25	Healthy population+ pediatric ALL	-	7 (4.82)	-	1 (0.68)	-	6 (4.13)
Iyer et al. <sup>13</sup>	Mumbai	225	Healthy population	-	10 (4.44)	-	3 (1.33)	3 (1.33)	4 (1.77)
Dhawan et al. <sup>14</sup>	Lucknow	500	Head and neck cancer patients	-	57 (11.4)	14 (2.80)	-	16 (3.20)	27 (5.40)
Dorababu et al. <sup>15</sup>	Hyderabad	90	Pediatric ALL	-	4 (4.44)	-	-	-	4 (4.44)
Current study	Punjab	454	IBD	1 (0.22)	23 (5.06)	4 (0.88) <sup>a</sup>	9 (1.98)	16 (3.52) <sup>a</sup>	13 (2.86) <sup>a</sup>

Values are presented as number (%).

<sup>a</sup>Eight (1.76%) patients were compound heterozygotes for both TPMT\*3A and TPMT\*3C and six (1.32%) patients were compound heterozygous for TPMT\*3B and TPMT\*3C.

<sup>b</sup>One of these patients was compound heterozygous with TPMT\*2 variant as the other allele.

NUDT, nudix hydrolase; TPMT, thiopurine S-methyltransferase; IBD, Inflammatory bowel disease; AIH, autoimmune hepatitis; ALL, acute lymphoblastic leukemia.

## SUPPLEMENTARY REFERENCES

1. Banerjee R, Ravikanth VV, Pal P, et al. NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India. *Aliment Pharmacol Ther* 2020;52:1683-1694.
2. Davavala SK, Desai DC, Abraham P, Ashavaid T, Joshi A, Gupta T. Prevalence of TPMT polymorphism in Indian patients requiring immunomodulator therapy and its clinical significance. *Indian J Gastroenterol* 2014;33:41-45.
3. Desire S, Balasubramanian P, Bajel A, et al. Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. *Med Oncol* 2010;27:1046-1049.
4. Shah SAV, Paradkar MU, Desai DC, Ashavaid TF. Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity. *Drug Metab Pers Ther* 2018;33:57-60.
5. Umamaheswaran G, Krishna Kumar D, Kayathiri D, et al. Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population. *Mol Biol Rep* 2012;39:6343-6351.
6. Sadik A, Ali Mahammad S, Am S, et al. Thiopurine methyltransferase as a therapeutic indicator of purine analogues: a preliminary study in southern metropolis. *J Gastroenterol Hepatol* 2013;26:1375-1379.
7. Naushad SM, Janaki Ramaiah M, Kutala VK, Hussain T, Alrokayan SA. Pharmacogenetic determinants of thiopurines in an Indian cohort. *Pharmacol Rep* 2021;73:278-287.
8. Murugesan R, Vahab SA, Patra S, et al. Thiopurine S-methyltransferase alleles, TPMT(\*)2, (\*)3B and (\*)3C, and genotype frequencies in an Indian population. *Exp Ther Med* 2010;1:121-127.
9. Linga VG, Patchva DB, Mallavarapu KM, et al. Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia. *Indian J Med Paediatr Oncol* 2014;35:276-280.
10. Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. *Cancer Chemother Pharmacol* 2019;83:341-348.
11. Kapoor G, Sinha R, Naithani R, Chandgothia M. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia. *Leuk Res* 2010;34:1023-1026.
12. Kapoor G, Maitra A, Somlata, Brahmachari V. Application of SNaPshot for analysis of thiopurine methyltransferase gene polymorphism. *Indian J Med Res* 2009;129:500-505.
13. Iyer SN, Tilak AV, Mukherjee MS, Singhal RS. Genotype frequencies of drug-metabolizing enzymes responsible for purine and pyrimidine antagonists in a healthy Asian-Indian population. *Biochem Genet* 2012;50:684-693.
14. Dhawan A, Ruwali M, Pant MC, Rahman Q, Parmar D. Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases. *Asia Pac J Clin Oncol* 2017;13:e11-e20.
15. Dorababu P, Nagesh N, Linga VG, et al. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. *Eur J Clin Pharmacol* 2012;68:379-387.